Skip to content

The Roles and Mechanisms of Chiral Materials in Wound Regeneration

The Roles and Mechanisms of Chiral Materials in Wound Regeneration

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500115786
Enrollment
Unknown
Registered
2025-12-31
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

wound healing

Interventions

Control group:NA
Scar wound group:NA

Sponsors

Shanghai Sixth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Healthy Participants (1) Aged between 18 and 65 years (inclusive). (2) Voluntarily agreed to participate in the study and signed the informed consent form. (3) Availability of surplus skin tissue during debridement procedures. (4) No history of major infectious diseases (e.g., hepatitis B, human immunodeficiency virus [HIV] infection). (5) Non-scar-forming constitution, defined as a Vancouver Scar Scale (VSS) score of 0 . 2. Patients with Hypertrophic Scarring (1) Aged between 18 and 65 years (inclusive). (2) Pathologically confirmed diagnosis of hypertrophic scarring, with a VSS score > 5 . (3) No prior scar-related treatments (e.g., laser therapy, surgical excision) within 1 year before enrollment. (4) Voluntarily agreed to participate in the study and signed the informed consent form. (5) Availability of surplus scar tissue during debridement procedures.

Exclusion criteria

Exclusion criteria: Common Exclusion Criteria 1. Females who were pregnant or lactating. 2. Presence of coagulation dysfunction (e.g., international normalized ratio [INR] > 1.5 or activated partial thromboplastin time [APTT] > 1.5 times the upper limit of the normal reference range). 3. Administration of immunosuppressants or glucocorticoids within the preceding 6 months. 4. Comorbidities of severe cardiopulmonary diseases (e.g., New York Heart Association [NYHA] functional class ? or higher) or acute hepatic/renal failure. 5. Infected wounds or active infectious foci (evidenced by white blood cell [WBC] count > 12 × 10?/L or C-reactive protein [CRP] level > 10 mg/L).

Design outcomes

Primary

MeasureTime frame
Differences in gene expression, signaling pathway activity, and histological features;

Secondary

MeasureTime frame
Wound healing rate;

Countries

China

Contacts

Public ContactCunyi Fan

Shanghai Sixth People’s Hospital

cyfan@sjtu.edu.cn+86 189 3017 7799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026